Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia

Journal of Clinical Psychopharmacology
Leonardo CorteseRaj Harricharan

Abstract

Persistent neuroleptic-induced movement disorders limit effective pharmacological management of psychotic disorders. Although antipsychotic switching is a common strategy for managing extrapyramidal side effects (EPSs), there is insufficient empirical support to guide the clinician. We designed the present study to examine whether patients with preexisting EPS switched to quetiapine would show greater reduction in EPS compared with control patients. Twenty-two patients with schizophrenia meeting clinical criteria for tardive dyskinesia or coexisting parkinsonism were randomized either to switch from their current antipsychotic to quetiapine (n = 13) or to remain on their current treatment (n = 9). A battery of standard clinical assessments for EPS along with electromechanical instrumental measures was administered before randomization and again 1 and 3 months postrandomization. We observed significant reduction in parkinsonism (P < 0.001) and akathisia (P = 0.02) based on clinical assessments and dyskinesia (P < 0.05) based on instrumental assessment for the quetiapine group. Subjects remaining on current treatment exhibited an increase in rigidity (P < 0.05) based on instrumental measures. These findings support the switching ...Continue Reading

References

Jan 1, 1990·The Journal of Neuropsychiatry and Clinical Neurosciences·M P Caligiuri, J B Lohr
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1982·Archives of General Psychiatry·G F JohnsonJ M Rey
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, J M Kane
Oct 15, 1998·The Journal of Clinical Psychiatry·S AhmedN R Schooler
May 9, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·A M BoganT Suppes
Apr 21, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·O GefvertL Lindström
Jan 5, 2002·CNS Drugs·Daniel TarsyFrank I Tarazi
Aug 15, 2002·International Clinical Psychopharmacology·K Alptekin, B B Kivircik
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Oct 6, 2005·Journal of Psychopharmacology·Peter J Weiden
Dec 8, 2006·The American Journal of Psychiatry·Susan M EssockJeffrey A Lieberman
Jan 1, 2003·International Journal of Psychiatry in Clinical Practice·A De NayerCa Altman

❮ Previous
Next ❯

Citations

Apr 21, 2009·Current Opinion in Psychiatry·Rajeev Kumar, Perminder S Sachdev
Oct 9, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Heather RigbyMandar Jog
May 14, 2011·The American Journal of Geriatric Pharmacotherapy·Maria Andrea Baez, Jonathan Avery
Dec 1, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Olga GurizOkan Ekinci
Jun 30, 2010·Journal of Neurodevelopmental Disorders·Agustini UtariRandi J Hagerman
Sep 8, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ali CaykoyluYakup Albayrak
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Sep 6, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yi-Cheng Hou, Chien-Han Lai
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Nov 20, 2013·The Cochrane Database of Systematic Reviews·Laila AsmalStefan Leucht
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·T Scott Stroup, Neil Gray
Nov 18, 2008·Journal of Clinical Psychopharmacology·Maria R Urbano, J Catesby Ware
Nov 17, 2009·Journal of Clinical Psychopharmacology·Gerd WillmundUndine E Lang
Feb 6, 2019·Current Opinion in Psychiatry·Christian G Widschwendter, Alex Hofer
Jul 15, 2015·Clinical Neuropharmacology·Philippos GourzisPanagiotis Polychronopoulos
Jul 21, 2017·Expert Review of Neurotherapeutics·Stanley N CaroffBenjamin Carroll
Aug 15, 2021·Neuropsychopharmacology Reports·UNKNOWN Japanese Society of Neuropsychopharmacology
Mar 30, 2019·Psychotherapy and Psychosomatics·David Cohen, Alexander Recalt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

European Archives of Psychiatry and Clinical Neuroscience
D P Bassitt, M R Louzã Neto
The British Journal of Psychiatry : the Journal of Mental Science
Jeffrey A LiebermanJohn M Kane
Archives of General Psychiatry
K H LittrellC D Peabody
© 2021 Meta ULC. All rights reserved